Oncorena is focused on developing a novel treatment for metastatic renal cancer, specifically targeting the two most common forms: Clear-Cell Carcinoma and Papillary Renal Carcinoma. The company is advancing a drug candidate known as ONC175, which is a synthetically produced active ingredient derived from orellanine, a naturally occurring substance found in certain mushrooms from the Cortinarius family. Preclinical studies have demonstrated that ONC175 exhibits powerful anti-tumor effects and selectively targets kidney cancer cells through specific uptake mechanisms. This selectivity is facilitated by solute carriers that are predominantly expressed on renal cancer cells, allowing for a targeted therapeutic approach that aims to improve clinical outcomes for patients.

Currently, Oncorena has completed all preclinical studies and has initiated a Phase I/II clinical trial to evaluate the safety, tolerability, and anti-tumor efficacy of ONC175 in patients with metastatic renal cancer. The trial, named Oncorella-1, is being conducted in collaboration with the Karolinska University Hospital in Stockholm, Sweden, and has received regulatory approval from the Swedish Medical Products Agency. The company aims to provide a treatment option that not only addresses a significant unmet medical need but also offers a favorable adverse event profile, particularly for patients on dialysis due to chronic kidney disease. The promising stability and scalability of ONC175 further support its potential for commercial production and widespread use.

Sweden

Oncorena is aiming to save human lives by transforming a natural substance into a breakthrough therapy treatment for advanced kidney cancer. We have completed all preclinical studies and are moving into early-stage clinical development. The objective is to confirm the powerful anti-tumor activity of our drug candidate - based on the natural substance orellanine - in advanced kidney cancer patients. Oncorena AB is headquartered in Lund, Sweden.

Oncorena

Company Details